March 22, 2024Cancer Research

Immune Profiling Predicts Response to Ipilimumab and Nivolumab in Metastatic Melanoma

View Full Paper

Ask AI

Bookmark

Authors

JBJoanna BagińskaDana-Farber Cancer Institute JCJiajia ChenBroad Institute GTGiuseppe TarantinoBroad Institute

Discussion

Member takes

Implication

Single-cell profiling demonstrates dynamic immune shifts and response biomarkers in metastatic melanoma, indicating that circulating cells may predict checkpoint blockade efficacy.

Key Points

Effector phenotypes in CD8+ T cells expanded following combination checkpoint blockade, accompanied by broad activation across adaptive and innate immune compartments.
Across 89 patients, elevated regulatory T cells one month after therapy initiation predicted improved progression-free survival and overall survival during treatment.
Cytometry by time-of-flight profiling supports circulating immune biomarkers to identify metastatic melanoma patients likely to benefit from ipilimumab and nivolumab.

Cite This Study

Bagińska et al. (2024) studied this question.

synapsesocial.com/papers/68e72f4bb6db6435876a87fb https://doi.org/10.1158/1538-7445.am2024-6397

View Full Paper

Ask AI

Bookmark

Implication

Single-cell profiling demonstrates dynamic immune shifts and response biomarkers in metastatic melanoma, indicating that circulating cells may predict checkpoint blockade efficacy.

Immune Profiling Predicts Response to Ipilimumab and Nivolumab in Metastatic Melanoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Immune Profiling Predicts Response to Ipilimumab and Nivolumab in Metastatic Melanoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider